



COLORADO

Department of Health Care
Policy & Financing

DUR BOARD MEETING AGENDA

March 23, 2021

3:30 p.m. - 5:30 p.m. Open Session

Zoom Link will be posted at

<https://www.colorado.gov/pacific/hcpf/drug-utilization-review-board>
prior to the meeting

Health First Colorado, Colorado Medicaid
Drug Utilization Review Board

DUR Board Members	CO-DUR Team
Allison Blackmer, PharmD (Chair)	Jeffrey Taylor, PharmD (HCPF)
Michael Noonan, DO	Rachele Crane, PharmD (HCPF)
Miroslav Anguelov, PharmD	Julia Rawlings, PharmD (CO-DUR)
Todd Brubaker, DO	Robert L Page II, PharmD, MSPH (CO-DUR)
Liza Wilson Claus, PharmD	Heather Anderson, PhD (CO-DUR)
William Lai, PharmD, MBA	Garth Wright, MPH (CO-DUR)
Patricia Lanius, MHA, RPh	Gina Moore, PharmD, MBA (CO-DUR)
Alison Shmerling, MD, MPH (Vice Chair)	Vanessa Patterson, MPH (CO-DUR)
Scott VanEyck, MD	

1. Call to Order and Board Member Roll Call, and Introductions

2. Announcements

3. Reading of Rules for Public Testimony and Disclosure of Conflicts of Interest

- Agenda items must be approved in advance, including requests to present information. Please contact the DUR Pharmacist, Jeff Taylor, at jeffrey.taylor@state.co.us with questions.
- Anyone wishing to provide testimony must contact the DUR Pharmacist at least 24 hours before the meeting.

Open Session:

4. New Business (open for public testimony and board review)

Proposed Prior Authorization Criteria for Medical Benefit Physician Administered Drug Products

Our mission is to improve health care access and outcomes for the people we serve while demonstrating sound stewardship of financial resources.

www.colorado.gov/hcpf



(Products included for review in this section are identified by HCPCS J Code billing codes. Information regarding specific product formulations included in a listed J Code is available by referencing Appendix X at <https://www.colorado.gov/hcpf/billing-manuals#appendices> .)

- Neuromuscular Agents
 - Botox J0585
 - Myobloc J0587
 - Dysport J0586
 - Xeomin J0588
- Bone Resorption Inhibitor Agents
 - Prolia, Xgeva J0897
- Monoclonal Antibody Agents
 - Xolair J2357
 - Nucala J2182
 - Fasenra J0517
 - Cinqair J2786
 - Remicade J1745
 - Soliris J1300
 - Entyvio J3380
- Multiple Sclerosis Agents
 - Ocrevus J2350
 - Tysabri J2323
- Immune Globulin Agents
 - Gammaked, Gamunex-C, Gamunex J1561
 - Octagam 5%, 10% J1568
 - Gammagard Liquid J1569
 - Privigen J1459
 - Asceniv, Gammaplex, Panzyga J1599
 - Bivigam J1556
 - Flebogamma DIF J1572
 - Gammagard S/D J1566
 - Gammaplex J1557

5. Adjournment

Reasonable accommodations will be provided upon request for persons with disabilities. Please notify the Board Coordinator at jeffrey.taylor@state.co.us or the 504/ADA Coordinator hcpf504ada@state.co.us at least one week prior to the meeting to make arrangements.

